Drugs / NAV-240
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06933043 | May → Nov 2025 | — | Navigator Medicines, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06181786 | Nov 2023 → Sep 2024 | — | Navigator Medicines, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07384975 | Jan 2026 → Sep 2027 expected | hidradenitis suppurativa | Navigator Medicines, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NAV-240 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07384975 ↗ |
| Route | Intravenous | “Single intravenous (IV) administration of ascending dose levels of NAV-240” NCT06181786 ↗ |